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Abstract
Background: The overall prevalence of thrombocytopenia in neonates admitted to neonatal intensive care units
ranges from 22 to 35%. There are only a few small studies that outline the relationship between the severity of
thrombocytopenia and the risk of bleeding. This makes it difficult to form an evidence-based threshold for platelet
transfusions in neonatal patients. The aim of this study was to determine the prevalence of thrombocytopenia in a
tertiary neonatal intensive care unit and to study the relation between thrombocytopenia and the risk of
intraventricular hemorrhage (IVH).
Methods: We performed a retrospective cohort study of all patients with thrombocytopenia admitted to our
neonatal tertiary care nursery between January 2006 and December 2008. Patients were divided into 4 groups
according to the severity of thrombocytopenia: mild (100-149 × 10
9/L), moderate (50-99 × 10
9/L), severe (30-49 ×
10
9/L) or very severe (< 30 × 10
9/L). The primary outcome was IVH ≥ grade 2. Pearson’s chi-squared and Fischer’s
exact tests were used for categorical data. ANOVA, logistic regression analysis and multivariate linear regression
were used for comparisons between groups and for confounding factors.
Results: The prevalence of thrombocytopenia was 27% (422/1569). Risk of IVH ≥ grade 2 was 12% (48/411) in
neonates with versus 5% (40/844) in neonates without thrombocytopenia (p < 0.01). After multivariate linear
regression analysis, risk of IVH ≥ grade 2 in the subgroups of thrombocytopenic infants was not significantly
different (p = 0.3).
After logistic regression analysis the difference in mortality rate in neonates with and without thrombocytopenia
was not significant (p = 0.4). Similarly, we found no difference in mortality rate in the subgroups of neonates with
thrombocytopenia (p = 0.7).
Conclusion: Although IVH ≥ grade 2 occurs more often in neonates with thrombocytopenia, this relation is
independent of the severity of thrombocytopenia. Prospective studies should be conducted to assess the true risk
of hemorrhage depending on underlying conditions. Randomized controlled trials are urgently needed to
determine a safe lower threshold for platelet transfusions.
Background
The overall prevalence of thrombocytopenia in neonates
ranges from 1 to 5% [1-3] and is reported to be much
higher in neonates admitted to neonatal intensive care
units, ranging from 22 to 35% [1-6]. From 22 weeks’
gestation onwards, the platelet count reaches and
maintains a level above 150 × 10
9/L, thereby defining
thrombocytopenia in the newborn as a platelet count
below 150 × 10
9/L [1,2]. Many neonatal and maternal
conditions are associated with thrombocytopenia, of
which septicemia and prematurity are the most common
[2,6]. In thrombocytopenia the major concern is an
increased risk of bleeding.
In 1882 Bizzozzero was the first to describe the role of
platelets in coagulation and thrombosis [7]. Since then,
only a few small studies investigating the relationship
between the severity of thrombocytopenia and the risk
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Likewise, the number of clinical trials examining throm-
bocytopenia and the effects on bleeding in adults is
limited [10-13]. The lack of studies makes it difficult to
form an evidence-based threshold for platelet transfu-
sions in neonatal patients.
The aim of this study was to analyze and describe all
cases with thrombocytopenia admitted to our neonatal
nursery during a 3-year period and study a possible rela-
tionship between the risk of intraventricular hemorrhage
(IVH) and the severity of thrombocytopenia. We studied
the prevalence and risk factors of thrombocytopenia in
relation to the risk of IVH and mortality.
Methods
Patients
We retrospectively collected data from all neonates
admitted between January 2006 and December 2008 to
the neonatal department of the Leiden University
Medical Center, a tertiary neonatal care center in The
Netherlands. In the Netherlands no ethical approval is
required for this type of research as no new intervention
or treatment is studied. Nor is any randomization
needed. All collected data was anonymized. We identi-
fied all thrombocytopenic newborns by extracting data
from our dedicated patient-database, medical files,
laboratory system and electronic blood banking records.
We excluded neonates with only one platelet count
measurement below 150 × 10
9/l. We considered these
isolated counts as clotted samples, platelet clumping,
laboratory error or one-timeo n l ym e a s u r e m e n t sw i t h
immediate normalization. Thrombocytopenia was
defined as a platelet count below 150 × 10
9/L. The
included neonates with thrombocytopenia were divided
into 4 groups, based on their lowest platelet count during
their stay in our unit, and classified as mild (platelet count
100-149 × 10
9/L), moderate (platelet count 50-99 × 10
9/L),
severe (platelet count 30-49 × 10
9/L) or very severe (plate-
let count < 30 × 10
9/L), according to standard classification
[1,2,6,14-17].
We recorded the presence of IVH detected by cranial
ultrasound and classified according to Volpe [18]. IVH
grade 2, grade 3 or grade 4 (i.e. periventricular hemor-
rhagic infarction (PVHI)) were recorded.
Cranial ultrasounds were performed according to local
protocol depending on gestational age and degree of
illness.
Data for demographic as well as clinical conditions of
all infants were collected, including gender, gestational
age at birth, birth weight, small for gestational age, chro-
mosomal disorders, perinatal asphyxia, necrotizing
enterocolitis, sepsis/meningitis, hemorrhage, thrombosis,
central catheters, polycythemia, rhesus hemolytic dis-
ease, exchange transfusion, neonatal allo-immune
thrombocytopenia and the number of blood product
transfusions (platelets, erythrocytes, fresh frozen
plasma). Small for gestational age was defined as a birth
weight < 3
rd percentile for the corresponding gestational
age [19]. Chromosomal disorders were defined as conge-
nital anomalies related to thrombocytopenia, such as
trisomy 18 and 21. Perinatal asphyxia was defined as a
five minute Apgar score < 5, a decelerative heart rate on
a cardiotocogram and/or an arterial umbilical cord pH
below 7.0. Hypotension was defined as a mean blood
pressure below the 3
rd percentile for gestational age and
requiring inotropic support. Sepsis was defined as a
positive blood culture in a neonate with clinical signs of
infection. Necrotizing enterocolitis was scored based on
Bell staging criteria [20]. Polycythemia was defined as a
venous hematocrit ≥ 65% in symptomatic infants or ≥
70% with or without symptoms. A thrombus could be
catheter related, in a major blood vessel or intracardial,
detected with ultrasound.
T h ep r i m a r yo u t c o m em e a s u r ew a sI V H≥ grade 2.
The secondary outcomes were total number of platelet
transfusions and mortality.
In our hospital a platelet transfusion for neonates is a
concentrated single donor product in plasma and is leu-
kocyte depleted. The dose is a median of 20 × 10
9 plate-
lets per kg. The product is irradiated with 25 Gy for all
infants with a gestational age below 32 weeks and/or a
birth weight below 1500 grams and/or for neonates that
previously underwent an intra-uterine transfusion.
Guidelines for platelet transfusions in our department
were as follows: 1) platelet count < 30 × 10
9/L and
stable, 2) platelet count < 50 × 10
9/L and unstable, and/
or birth weight < 1000 g, and/or previous major bleed-
ing, and/or after exchange transfusion, and/or before
planned surgery and/or rapid decrease of platelets, or
3) platelet count < 100 × 10
9/L in neonates with active
bleeding and/or at start of exchange transfusion [17].
Statistics
Data analyses were performed using Statistical Package
for Social Sciences (SPSS), version 16.0 (SPSS, Inc.,
Chicago, Illinois, USA). For every separate variable the
Pearson’s chi-squared test was used. If the chi-squared-
test could not be used (frequency of an event was
<5 )t h eF i s h e r ’s exact test was used. Comparisons
between group means were analyzed using the one way
ANOVA test (with a 95% confidence-interval). Logistic
regression was performed to evaluate the confounders
between the infants with and without thrombocytopenia.
Factors considered potential confounders were variables
with a significant difference in thrombocytopenia. Multi-
variate linear regression was used to compare for con-
founders in the subgroups of thrombocytopenic
neonates, because of the small number in some of the
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smaller than 0.05 was considered to be significant.
Results
Total patient population
A total of 1727 neonates were admitted to our neonatal
nursery during the 3-year study period. Thrombocytope-
nia was detected in 580 neonates, of which 158 were
excluded because of only one platelet count below 150 ×
10
9/L. The prevalence of thrombocytopenia was 27%
(422/1569). Neonates with thrombocytopenia were
divided into four groups according to their lowest platelet
count; 122 (29%) mild, 164 (39%) moderate, 67 (16%)
severe and 69 (16%) with very severe thrombocytopenia.
The distribution of included and excluded neonates is
shown in Figure 1.
An overview of the baseline characteristics of all
included neonates with (n = 422) and without (n =
1147) thrombocytopenia is presented in Table 1. Except
for gender, single or multiple births and chromosomal
disorders, every characteristic was significantly different.
Primary and secondary outcome in total patient
population
Cranial ultrasound was performed in 97% (411/422) of
neonates with thrombocytopenia and in 74% (844/1147)
of infants without thrombocytopenia. The rate of IVH ≥
grade 2 in neonates with and without thrombocytopenia
was 12% (48/411) and 5% (40/844), respectively (p <
0.01). After multiple regression analysis, with all
significantly different variables, the correlation between
IVH and thrombocytopenia was still statistically signifi-
cant (p = 0.045); gestational age remained an indepen-
dent significant risk factor for IVH (p < 0.01).
Mortality rate in neonates with and without thrombo-
cytopenia, respectively 9% (39/422) vs. 3% (32/1147),
was not significantly different after multiple regression
analysis (p = 0.4).
Thrombocytopenic patient population
Thrombocytopenia was detected at a mean of 2 days
after birth (range 0-56 days). In the group of thrombo-
cytopenic neonates (n = 422), 27 died before thrombo-
cytopenia had resolved and in 32 neonates laboratory
testing was discontinued before a platelet count above
150 × 10
9/L was recorded during follow-up. In these 32
infants platelet counts were not measured because of
already increasing platelet counts with a value above
120 × 10
9/L. In the remaining 363 neonates, the mean
duration of thrombocytopenia was 9 days (range 0-112
days). We found a significant positive correlation
between severity of thrombocytopenia and the time to
recovery. Duration of thrombocytopenia in the mild,
moderate, severe and very severe group was 5, 8, 10 and
16 days, respectively (p < 0.01).
Mean gestational age at birth was 32.5 (range 24 to 42)
weeks. Of all thrombocytopenic neonates, 75% (316/422)
were preterm (<37 weeks). Patient characteristics divided
into subgroups according to severity of thrombocytope-
nia are shown in Table 2. After linear regression analysis,
Total number of 
Neonates
1727
Thrombocytopenia
580 (34%)
No Thrombocytopenia
1147 (66%)
Mild (100-149x10
9/L)
122 (29%)
Moderate (50-99x10
9/L)
164 (39%)
Excluded 
158 (27%) 
(1 x plateletcount <150x10
9.L)
Mortality
32 (3%)
Severe (30-49x10
9/L)
67 (16%)
Very severe (< 30x10
9/L)
69 (16%)
Included
422 (73%)
(> 1 x plateletcount <150x10
9/L)
Mortality
17 (10%)
Mortality
7 (10%)
Mortality
7 (10%)
Mortality
8 (7%)
IVH
12/117 (10%)
IVH
22/160 (14%)
IVH
4/66 (6%)
IVH
10/68 (15%)
IVH
22 (3%)
Figure 1 Flow-chart of all in- and exclusions of the cohort.
von Lindern et al. BMC Pediatrics 2011, 11:16
http://www.biomedcentral.com/1471-2431/11/16
Page 3 of 7severity of thrombocytopenia remained associated with
sepsis (p < 0.01) and thrombi (p < 0.01).
In 66% of the 105 thrombocytopenic neonates with
sepsis, the low platelet count was already present before
the child became ill, whereas in 15% thrombocytopenia
developed after the onset of sepsis.
Primary and secondary outcome in thrombocytopenic
patient population
In the majority (87%) of neonates with an IVH ≥ grade
2 the hemorrhage occurred within the first 3 days of
life. In 23% of the 48 neonates (11/48) with an IVH, the
hemorrhage was discovered on the same day as the
Table 1 Patient characteristics of neonates with and without thrombocytopenia
Neonates without thrombocytopenia
(N = 1147)
Neonates with thrombocytopenia
(N = 422)
P-value
Female gender, n (%) 513 (45) 179 (42) 0.41
GA at birth (weeks), mean ± SD 35 ± 4.2 32.5 ± 4.8 <0.01
Birth weight (gram), mean ± SD 2537 ± 968 1864 ± 1067 <0.01
SGA, n (%) 44 (4) 62 (15) <0.01
Multiple births (single), n (%) 270 (24) 100 (24) 0.96
Postnatal condition
Asphyxia, n (%) 42 (4) 46 (11) <0.01
Hypotension, n (%) 68 (6) 123 (29) <0.01
Sepsis, n (%) 77 (7) 129 (30) <0.01
NEC, n (%) 9 (1) 10 (2) 0.01
Central catheter, n (%) 403 (35) 346 (82) <0.01
Thrombus, n (%) 6 (1) 14 (3) <0.01
NAITP, n (%) 1 (0) 14 (3) <0.01
Polycythemia, n (%) 32 (3) 26 (6) <0.01
RHD, n (%) 61 (5) 40 (10) <0.01
Exchange transfusion, n (%) 1 (0) 14 (3) <0.01
Chromosomal disorders, n (%) 9 (1) 7 (2) 0.15
GA = gestational age, SGA = small for gestational age, NEC = necrotizing enterocolitis, NAITP = Neonatal alloimmune thrombocytopenia, RHD = Rhesus
Hemolytic Disease.
Table 2 Patient characteristics of thrombocytopenic neonates, divided into subgroups by severity
Mild
(100-149 × 10
9/L)
(N = 122)
Moderate
(50-99 × 10
9/L)
(N = 164)
Severe
(30-49 × 10
9/L)
(N = 67)
Very severe
(<30 × 10
9/L)
(N = 69)
P-value
Gender (female), n (%) 51 (42) 66 (40) 32 (48) 30 (43) 0.77
GA (weeks), mean ± SD 32.8 ± 4.7 32.1 ± 4.7 32.5 ± 4.7 32.9 ± 5.0 0.56
Weight (gram), mean ± SD 2004 ± 1172 1715 ± 984 1854 ± 1058 1979 ± 1046 0.11
SGA, n (%) 13 (11) 29 (18) 12 (18) 8 (12) 0.28
Postnatal condition
Asphyxia, n (%) 11 (9) 14 (9) 9 (13) 12 (17) 0.19
Hypotension, n (%) 27 (22) 46 (28) 28 (42) 22 (32) 0.04
Sepsis, n (%) 26 (21) 43 (26) 25 (37) 35 (51) <0.01
NEC, n (%) 1 (1) 4 (2) 3 (4) 2 (3) *
Central catheter, n (%) 90 (74) 138 (84) 56 (84) 62 (90) 0.03
Thrombus, n (%) 2 (2) 3 (2) 3 (4) 6 (9) *
NAITP, n (%) 1 (1) 5 (3) 5 (8) 3 (4) *
Polycythemia, n (%) 6 (5) 12 (7) 3 (5) 5 (7) *
RHD, n (%) 7 (6) 13 (8) 8 (12) 12 (17) 0.05
Exchange transfusion, n (%) 1 (1) 4 (2) 2 (3) 7 (10) *
Chromosomal disorders, n (%) 0 (0) 2 (1) 1 (1) 4 (6) *
* = No analysis possible, because some of the subgroups were too small.
GA = gestational age, SGA = small for gestational age, NEC = necrotizing enterocolitis, FFP = fresh frozen plasma, NAITP = Neonatal alloimmune
thrombocytopenia, RHD = Rhesus Hemolytic Disease.
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rhage was discovered after and in 16 (33%) before the
thrombocytopenia even existed. In 1 neonate we could
not trace the timing of the hemorrhage.
Among the 122 neonates who received a platelet
transfusion 17 had an IVH ≥ grade 2. Two (13%) of
these infants developed an IVH during thrombocytope-
nia despite platelet transfusions (one IVH grade 2, one
IVH grade 3).
The primary and secondary outcome in the 4 sub-
groups of neonates with thrombocytopenia is presented
in Table 3. Risk of hemorrhage was 10% (12/117), 14%
(22/160), 6% (4/66) and 15% (10/68). We found no sig-
nificant association between bleeding and severity of
thrombocytopenia (p = 0.3). After logistic regression
analysis, the severity of thrombocytopenia was not a sig-
nificant risk factor for IVH.
Logistic regression analysis showed no significant rela-
tion between mortality and the severity of thrombocyto-
penia (p = 0.7). In 5 patients treatment was withdrawn
because of poor neurological prognosis due to major
hemorrhage (IVH grade 3 or PVHI) in combination
with respiratory and/or cardiac insufficiency.
Of all included neonates with thrombocytopenia 29%
(122/422) received a platelet transfusion (Table 3). The
median number of platelet transfusions in the mild,
moderate, severe and very severe groups was 0, 1, 1 and
3, respectively. The 9 neonates in the moderate throm-
bocytopenia group (50-99 × 10
9/L) were transfused
because of a rapid drop in platelet count in combination
with sepsis (n = 4), IVH ≥grade 2 (n = 3) or adrenal
hemorrhage (n = 1). In most cases the infants with
severe thrombocytopenia (30-49 × 10
9/L) received a pla-
telet transfusion before or during an intervention (such
as a lumbar puncture or exchange transfusion), because
of active bleeding or if they were clinically unstable. The
rest of the newborns were transfused when the platelet
count was below 30 × 10
9/L. Only 4 neonates with very
severe thrombocytopenia did not receive a platelet
transfusion. Three of them had a gestational age of 37
and the fourth one of 31 weeks. All four were clinically
stable, 2 had polycythemia and 2 had Rhesus hemolytic
disease. None of them had IVH.
Discussion
This study shows that although thrombocytopenic neo-
nates are a high risk group (more unstable, and sicker
than non-thrombocytopenic neonates), the severity of
thrombocytopenia is not related to IVH or mortality. In
33% of the thrombocytopenic neonates with IVH grade
2 or more, IVH occurred before the thrombocytopenia
even existed. Our data confirm that risk of IVH in neo-
nates is a complex mechanism related to a wide variety
of factors, of which low platelet counts is only one.
Prevalence of thrombocytopenia
The overall prevalence of thrombocytopenia found in
this study (27%) is in accordance with the rates reported
in the literature for tertiary care centers (22-35%) [1-6].
The prevalence of severe (<50 × 10
9/L) thrombocytope-
nia (8%) was also similar to other studies (2-25%) [1,3].
Our findings confirm that thrombocytopenia in neo-
nates is associated with a wide variety of factors, includ-
ing prematurity and low birth weight, small for
gestational age, sepsis, hypotension, necrotizing entero-
colitis, asphyxia, thrombi and exchange transfusions
[1,4,14,21].
Platelet transfusion
We found a positive correlation between the severity of
thrombocytopenia, the duration of thrombocytopenia
and with the total number of platelet transfusions. In
the subgroup of infants with severe thrombocytopenia,
platelet transfusion resulted in a good, but less sustained
rise in platelet count (data not shown). A few studies
have suggested that a fast drop in platelet count after
Table 3 Primary and secondary outcome in the 4 subgroups of thrombocytopenic neonates
Mild
(100-149 × 10
9/L)
Moderate
(50-99 × 10
9/L)
Severe
(30-49 × 10
9/L)
Very severe
(<30 × 10
9/l)
P-value
(N = 122) (N = 164) (N = 67) (N = 69)
Primary Outcome (N = 117) (N = 160) (N = 66) (N = 68)
Number of neonates with IVH≥ grade 2, n (%) 12 (10) 22 (14) 4 (6) 10 (15) 0.32
IVH, grade 2 3 (3) 7 (4) 3 (5) 6 (9) 0.26
IVH, grade 3 4 (3) 6 (4) 1 (2) 2 (3) 0.86
PVHI (i.e., IVH grade 4) 5 (4) 9 (6) 0 (0) 2 (3) 0.25
Secondary Outcome (N = 122) (N = 164) (N = 67) (N = 69)
Number of platelet Txs per transfused patient, median (range), N 0
(N = 0)
1 (1-1)
(N = 9)
1 (1-5)
(N = 48)
3 (1-28)
(N = 65)
< 0.01
Mortality, n (%) 8 (7) 17 (10) 7 (10) 7 (10) 0.69
IVH = intraventricular hemorrhage, PVHI = periventricular hemorrhagic infarction, Txs = transfusions.
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instead of platelet underproduction [21].
The reason for platelet transfusions in more than half
of the cases was an existing thrombocytopenia. Despite
the platelet transfusions, 13% (2/17) developed an IVH
(≥ grade 2), independent of the severity of thrombocyto-
penia. In newborns that required more transfusions
( d a t an o ts h o w n )n oi n c r e a s e dr i s kf o rI V Hw a ss e e n ,
comparable to other studies [9,16,21]. Therefore the jury
is still out on the protective value of platelet transfu-
sions [1,4,6,9,22].
Risk of hemorrhage
We found no significant relationship between hemor-
rhage and severity of thrombocytopenia. This suggests
that bleeding in neonates depends on more variables
than a platelet count alone. In approximately one-third
of the thrombocytopenic neonates the IVH was discov-
ered before the thrombocytopenia existed and this raises
the question whether IVH can be explained as a cause
or an effect of thrombocytopenia [22-24]. Hemorrhage
is probably due to pre-existing fragility in vessel wall
structure (especially in premature neonates) and
damaged blood vessels, amongst others by cytokines
and/or a co-existing coagulopathy [9,22].
Our results are important in the discussion whether
thrombocytopenia is one of the major causes of IVH in
neonates. Major IVH has a large impact on neurological
development and mortality. However, the risk for an
IVH cannot be predicted based on a platelet count
alone. We also looked at other bleedings of importance
in the thrombocytopenic neonates, such as pulmonary-
or gastrointestinal bleedings, but the number of these
hemorrhages was too small to analyze. Other variables
such as gestational age, birth weight and underlying ill-
ness are of equal importance and should be taken into
account. Several studies have searched for other factors
that may influence the development of hemorrhage in
thrombocytopenic neonates. Deficiencies, immaturity or
increased consumption of other blood products, such as
thrombopoietin, coagulation factors, megakaryocyte pro-
genitor cells, cytokines and mean platelet volume, have
been reported [3,25].
One of the current major issues in transfusion medi-
cine is the appropriate trigger for platelet transfusion.
Different triggers are being used for platelet transfusion.
While some centers transfuse all neonates with platelet
counts below 50 × 10
9/L, other centers use lower
thresholds such as < 30 or < 20 × 10
9/L [1,2,14,17,26].
There is an apparent evolvement amongst neonatolo-
gists towards more liberal platelet transfusion practices,
even in the absence of evidence based data [27]. This
study does not demonstrate a difference in IVH between
neonates with a platelet count below 50 × 10
9/L or
below 30 × 10
9/L (nor between <150, <100 or lower for
that matter), questioning the different transfusion
thresholds. Whether platelet transfusions have a protec-
tive value in neonates with a platelet count below 20 ×
10
9/L is still not known.
Conclusion
In this study, we found no relationship between the
severity of thrombocytopenia and IVH, suggesting that
the etiology of IVH in neonates is a complex multifac-
torial process. However, our findings should be inter-
preted with care due to limitations associated with the
retrospective nature of the study and the relatively small
sample sizes of some variables in the subgroups.
Prospective studies should be conducted to assess the
true risk of hemorrhage depending on underlying condi-
tions. Randomized controlled trials are urgently needed
to determine a safe lower threshold for platelet
transfusions.
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